Report

Breast Cancer Research and Treatment

, Volume 2, Issue 2, pp 163-169

Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer

  • Aman U. BuzdarAffiliated withMedical Breast Service-Department of Medicine, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute
  • , Terry L. SmithAffiliated withDepartment of Biomathematics, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute
  • , Kimberly C. PowellAffiliated withMedical Breast Service-Department of Medicine, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute
  • , George R. BlumenscheinAffiliated withMedical Breast Service-Department of Medicine, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute
  • , Edmund A. GehanAffiliated withDepartment of Biomathematics, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary

Four hundred and sixty patients with stage II or III breast cancer following regional therapy were treated with an adjuvant combination chemotherapy consisting of fluorouracil, doxorubicin, and cyclophosphamide (FAC). The relationship between the length of disease-free survival and length of delays in initiation of chemotherapy after surgery was evaluated. Patients were divided into four subgroups according to the length of delay in initiation of chemotherapy (< 10 weeks, 10–13, 14–17, and ≥ 18 weeks). Overall four year diseasefree survival was 64%, 68%, 60%, and 63% for patient groups with delays of < 10 weeks, 10–13, 14–17, or ≥ 18 weeks respectively (p = 0.39). There was no trend for longer delay in treatment to be associated with shorter disease-free survival, except in poor prognosis patients.

Keywords

adjuvant therapy delay breast cancer disease-free survival FAC